KALA BIO (KALA) Expected to Announce Earnings on Thursday

KALA BIO (NASDAQ:KALA) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($2.47) per share for the quarter.

KALA BIO Price Performance

Shares of NASDAQ:KALA opened at $6.70 on Wednesday. The company has a debt-to-equity ratio of 3.18, a quick ratio of 2.15 and a current ratio of 2.15. KALA BIO has a 52 week low of $4.21 and a 52 week high of $11.20. The firm has a market cap of $40.81 million, a PE ratio of -0.54 and a beta of -2.19. The firm’s fifty day moving average is $7.75 and its 200-day moving average is $6.81.

Insiders Place Their Bets

In other KALA BIO news, major shareholder Bros. Advisors Lp Baker purchased 310,559 shares of the firm’s stock in a transaction on Monday, December 30th. The stock was purchased at an average cost of $6.44 per share, for a total transaction of $1,999,999.96. Following the acquisition, the insider now owns 1,083,398 shares in the company, valued at approximately $6,977,083.12. The trade was a 40.18 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Mark T. Iwicki sold 5,779 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $7.63, for a total value of $44,093.77. Following the completion of the transaction, the chief executive officer now directly owns 280,076 shares in the company, valued at $2,136,979.88. This represents a 2.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 9,506 shares of company stock worth $72,531. 8.32% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of KALA BIO in a report on Thursday, February 13th.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.